Phase II study to evaluate the efficacy and safety of rilotumumab and bevacizumab (BEV) in subjects with recurrent malignant glioma (MG).
Year: 2012
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Mary Lou Affronti, Annick Desjardins, Henry S. Friedman, Katherine B. Peters, James E Herndon II, Frances McSherry, Eric S Lipp, Alise Brickhouse, Woody C Massey, Elizabeth Miller, Sprague Cheshire, Christina Cone, Katherine H Kalinowski, Jung-Young Kim, Harry H Lay, Victoria Poillucci, Cindy Southerland, Jill Tetterton, James J Vredenburgh
Institution: Duke Medical Center
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2891765009